Development and in vitro evaluation of Eudragit E100 and PVP based matrix films for the transdermal delivery of Repaglinid
Vijaya R, Uma Maheshwari S, Jaya Bharathi S
The study aims the feasibility of transdermal delivery of an antidiabetic agent Repaglinide for controlled and extended release by formulating as matrix film using Eudragit E100 and polyvinylpyrrolidone (PVP). The films were prepared by solvent evaporation technique and characterized in vitro for physico chemical properties, drug release and permeation across synthetic cellulose acetate membrane Effect of plasticizer concentration (20% w/w, 30%w/w and 40%w/w) penetration enhancers (menthol and propylene glycol+oleic acid) on drug release and permeation respectively were studied. Stability studies were conducted at ambient and accelerated conditions. Translucent flexible films of Repaglinide having uniform thickness, weight, folding endurance and drug content were formulated. A 30% w/w concentration of plasticizer in the film had produced higher drug release of 93.26%±0.46% in 14 h and the release was found to follow higuchi kinetics with diffusion mediated mechanism. The formulation Eudragit E100 and PVP (7:3) with 5% menthol as enhancer was chosen as an optimized formulation that effectively penetrated Repaglinide across the cellulose acetate membrane and thus suitable for transdermal delivery. The optimized film was stable at ambient conditions of storage with respect to drug content and release.
Franz Diffusion Cell
How to cite this article:
Vijaya R, Uma Maheshwari S, Jaya Bharathi S. Development and in vitro evaluation of Eudragit E100 and PVP based matrix films for the transdermal delivery of Repaglinid. Pharma Innovation 2015;3(12):16-23.